Details
Glinova Indications
Insulin type II diabetes when blood sugar levels can not be adequately maintain only diet, exercise and weight loss.
Contraindications
Hlinova not intended for the treatment of insulin-dependent diabetes type I, diabetic ketoacidosis, diabetic coma and prekomy, severe hepatic or renal function disorders.
Hlinova not be administered to patients with hypersensitivity to glimepiride or any auxiliary ingredient, which is part of the drug to sulfonylureas or other sulfonilamidnyh drugs (risk of hypersensitivity reactions).
Dosage & Administration
Successful treatment of diabetes depends on respect for the patient appropriate diet, regular physical activity, as well as continuous monitoring of blood glucose and urine. Failure patients diet can not compensate for taking pills or insulin.
The drug is used for adults.
Dosage depends on the results of tests of glucose in the blood and urine. The initial dose is 1 mg glimepiride per day. If the dose makes it possible to achieve controllable disease, it should be used for maintenance therapy.
If glycemic control is not optimal, the dosage should be increased to 2, 3 or 4 mg glimepiride per day gradually (at intervals of 1-2 weeks).
The dose of more than 4 mg per day gives better results only in rare cases.
The maximum recommended dose - 6 mg glimepiride per day.
